miDiagnostics offers an ultra-fast RT-qPCR SARS-CoV-2 test that combines the accuracy of a central, lab-based PCR test with the speed of an antigen test.
miDiagnostics is developing a molecular diagnostics pipeline, using its ultra-fast PCR technology for the detection of SARS-CoV-2.
With menu expansion possibilities towards other respiratory indications, sexual transmitted diseases and any other molecular test that could merit the benefits of decentralization, diagnostic accuracy, and ease of use. In parallel, portable cellular diagnostic devices are being developed, which could ultimately be used in the home setting (i.e., complete blood count monitoring). These include a nanofluidic processor for blood sample preparation and lens-free imaging for cell counting and characterization
Diagnostic testing still relies on sending samples to centralized laboratories, often leading to a delay in receiving results and incorrect or inefficient patient management.
Current alternatives either focus on speed, at the expense of accuracy, or focus on accuracy, but are not easy-to-use and fast enough to deliver a result in a decentralised setting.
miDiagnostics is developing innovative products to fill this gap – combining accuracy, convenience and speed.
Our proprietary reader and test card with silicon chip requires only a small sample, which is drawn through the test card using capillary forces and requires no pump or power.
The reader allows for ultra-fast PCR and the results with lab-quality sensitivity and specificity are visualized on a connected device in a user-friendly user interface
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention.”
“Proud to be leading a top team and together with our numerous partners to make a significant contribution to healthcare in general.”
“As a Non-Executive Director on miDiagnostics’ Board, I have been privileged to witness its continued development. I am very proud to see many years of hard work coming to fruition and providing value, facilitating the return to a normal way of life, with potential to move high quality testing closer to the patient.”
“This technology could aid the management of outbreaks in challenging settings, such as nursing homes and home care environments, allowing healthcare professionals to adjust their management decisions at the point of care. ”